Management of Sick Sinus Syndrome

Understanding Sick Sinus Syndrome

The European Society of Cardiology recommends permanent pacemaker implantation as the definitive treatment for sick sinus syndrome when bradyarrhythmia has been demonstrated to account for syncope, as it effectively relieves symptoms and improves quality of life 1, 2

The European Heart Society suggests that physiological pacing (atrial or dual-chamber) is superior to VVI pacing 2
Atrial-based rate-responsive pacing is preferred to minimize exertion-related symptoms 2
Dual-chamber rate-responsive pacemakers (DDDR) are commonly used 1
Newly developed atrial-based minimal ventricular pacing modes are recommended as alternatives to conventional DDDR pacing 1
Permanent pacemaker implantation lowers the risk of developing atrial fibrillation 2
Improves quality of life by reducing symptoms 2
May improve survival compared to no treatment, though survival primarily depends on underlying cardiac disease 2
Despite adequate pacing, syncope recurs in approximately 20% of patients during long-term follow-up due to associated vasodepressor reflex mechanisms 1, 2

The European Heart Society recommends eliminating medications that exacerbate bradycardia when possible 1, 2

Catheter ablation is the first-choice treatment for paroxysmal AV nodal reciprocating tachycardia, AV reciprocating tachycardia, or typical atrial flutter 1
For atrial fibrillation or atypical left atrial flutter, treatment should be individualized 1
Percutaneous cardiac ablative techniques may be considered for atrial tachyarrhythmia control 2

The presence of structural heart disease or left ventricular dysfunction may impact prognosis and treatment decisions 2
Consider biventricular pacing in patients with depressed left ventricular ejection fraction, heart failure, and prolonged QRS duration 1

Pacemaker implantation is indicated when there is a clear association between significant symptoms and bradycardia, as recommended by the American Heart Association 3

The European Society of Cardiology recommends that beta-blockers are contraindicated in patients with sick sinus syndrome 4, 5
Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) should be avoided, according to the European Society of Cardiology 5
Ivabradine should not be combined with non-dihydropyridine calcium channel blockers, as stated by the European Society of Cardiology 4

Atropine may be used temporarily for emergency management of symptomatic bradycardia, as suggested by the American College of Cardiology 6
Isoproterenol infusion can be used for temporary treatment of refractory symptomatic bradycardia, according to the American College of Cardiology 6

Patients with symptomatic sinus bradycardia awaiting pacemaker implantation should be monitored with continuous ECG monitoring until definitive pacing therapy is established, as recommended by the American Heart Association 7, 8
Asymptomatic sinus bradycardia does not require in-hospital monitoring, as untreated sinus node dysfunction does not influence survival, according to the American College of Cardiology 7, 8

When initiating negative chronotropic medications in patients with significant sinus bradycardia, monitoring may be considered on an individual basis, as suggested by the American Heart Association 7, 8
Out-of-hospital drug initiation should be avoided in patients with symptomatic sick sinus syndrome when using Class IC agents, such as flecainide or propafenone, due to the risk of sinus node dysfunction and atrioventricular block, as recommended by the American College of Cardiology 9
Dofetilide requires mandatory inpatient ECG monitoring for 3 days during initiation due to FDA requirements for QT prolongation and ventricular arrhythmia risk, as stated by the American Heart Association 7, 8, 10
Sotalol requires 48-72 hours of ECG monitoring with QT interval measurement, and monitor QT interval continuously; discontinue if QTc exceeds 500 ms, as recommended by the American College of Cardiology 11

Patients with complete heart block or long sinus pauses are prone to develop torsades de pointes and require monitoring until bradyarrhythmia resolves or permanent pacing is instituted, as recommended by the American Heart Association 11
Monitor for development of AV conduction disturbances, as almost all antiarrhythmic drugs can cause sinus node dysfunction and atrioventricular block, according to the American College of Cardiology 9

Do not initiate Class IC antiarrhythmics in patients with bundle-branch block or AV conduction disturbances without careful monitoring, as recommended by the American College of Cardiology 9